Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Puma Biotechnology, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologic diagnosis of NSCLC and current stage IIIB (with pleural effusion) or IV, not curable with conventional therapy. For Arm C, less than or equal to 20 pack-years smoking history and current non smoker. A pack year = number of packs of cigarettes smoked per day x years smoked.
Progression following at least 12 weeks of treatment with Tarceva or Iressa. (Arms A and B only)
ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2 (not declining within past 2 weeks).
Tumor sample available and adequate for analysis.
At least one measurable target lesion.
Adequate cardiac, kidney, and liver function
Adequate blood counts
You may not be if
More than 3 prior cytotoxic chemotherapy treatments for relapsed or metastatic disease.
Significant cardiac disease or dysfunction.
Prior treatment with anthracyclines with cumulative dose of \>400 mg/m\^2.
Active central nervous system metastases, as indicated by clinical symptoms and/or progressive growth.
Use of Tarceva or Iressa within 14 days of treatment day 1 (Arms A and B only).
Major surgery, chemotherapy, radiotherapy, investigational drugs, or other cancer therapy within 3 weeks of treatment day 1.
Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom.
Inability or unwillingness to swallow HKI-272 capsules.
Pregnant or breastfeeding women.
Clareo Health | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
